Amgen and AstraZeneca drug combo meets trial goal
AstraZeneca and Amgen report their cancer drug combination significantly improved overall survival rates in a late-stage trial for lung cancer. The therapy successfully targeted extensive-stage small cell lung cancer.
Xurve View
Insights:
Xurve View
ASTRAZENECA PLC and AMGEN INC paired their cancer therapies to improve overall survival rates in a late-stage trial. The combination targets first-line extensive-stage small cell lung cancer. The trial results mark a key milestone for both drug developers in expanding oncology pipelines.
